ESTRO meets Asia 2024 - Abstract Book

S214

Interdisciplinary – Lung

ESTRO meets Asia 2024

Lung cancer is the third most common cancer in Indonesia based on GLOBOCAN data 2020. However, this type of cancer is also the deadliest type of malignancy among all cancer cases. Based on the stages and histopathology, there are certain subtypes that will respond better to radiation therapy. This is the first study in Indonesia which assesses the utilization of radiotherapy for lung cancer patients.

Material/Methods:

We collected secondary data from a cohort of individuals diagnosed with lung cancer at radiotherapy centers located in Indonesia during the period of 2019 to 2021. The primary endpoint of this study is to evaluate pre-pandemic radiotherapy utilization rate (RUR) for lung cancer patients in Indonesia. There are two categories for RUR, namely optimal radiotherapy utilization rate (oRUR) and actual radiotherapy utilization rate (aRUR). We conducted a comprehensive process of data cleansing including elimination of double entries and analyzed data from radiotherapy centers across Indonesia. This analysis produced actual and optimal RUR for lung cancer patients. These data were also compared to data from other countries.

Results:

There are 2,261 patients in this study from 34 radiotherapy centers in Indonesia during the data collection period. Within this cohort, 689 patients (30.47%) were female, and 1,565 patients (69.21%) were male. Patients' ages varied from 19 to 95 years, and most of the common histopathology identified was non-small cell lung cancer (95.3%), with cancer stage IV being predominant. We found that the number of oRUR in lung cancer patients was 86.9% (72.8 – 90.2%). The number of aRUR was 17.42%. Based on these findings, we also calculated the percentage of unmet need for lung cancer to be 79.97% (76.09 – 80.70%). We compared these data with results from other countries. Based on the data from Collaboration for Cancer Outcomes, Research & Evaluation (CCORE) Australia in 2013, oRUR was reported to be 77%, in Canada it was 62%, and across Europe, it ranged from 77 – 82%. For aRUR, these numbers were estimated to be around 25 – 53%.

Conclusion:

Underutilization of radiotherapy for lung cancer patients still persists. This problem was highlighted based on the percentage of unmet need in this study. Further research should be able to identify factors related to these existing problems.

Keywords: radiotheray utilization rate, lung cancer

References:

1.

Global Cancer Observatory. Cancer Incidence in Indonesia 2020. (2020). Available from:

https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf

2. Delaney G, Jacob S, Featherstone C, Barton M. The Role of Radiotherapy in Cancer Treatment. Am Cancer Soc.

2005;104:1129–37.